Active music therapy in dementia: results from an open-label trial

• Main Author: Aleixo,Mariângela Aparecida Rezende
• Publication Date: 2022
• Other Authors: Borges,Margarete Borges de, Gherman,Bruno Rabinovici, Teixeira,Ivan Abdala, Simões Neto,José Pedro, Santos,Raquel Luiza, Dourado,Marcia Cristina Nascimento, Marinho,Valeska
• Format: Article
• Language: eng
• Source: Jornal Brasileiro de Psiquiatria (Online)
• Download full: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0047-20852022000200117
• topic: Music therapy; dementia; Alzheimer’s disease; neuropsychiatric symptoms; cognition

ABSTRACT Objective: Cognitive, neuropsychiatric and functional deficits are core symptoms of dementia. Non-pharmacological interventions, such as music therapy, when used in conjunction with pharmacological treatment, have the potential to alleviate these symptoms. The purpose of this preliminary study is to examine the active music therapy on cognition and neuropsychiatric symptoms in the elderly with mild and moderate dementia. Methods: The initial sample consisted of outpatients with dementia (N = 15) and their family members or caregivers (N = 15). Two dyads did not complete the assessments before intervention and were excluded from the analysis. Thirteen females (N = 13) comprised the final sampled and were diagnosed with Alzheimer’s disease (N = 10), vascular dementia (N = 2) and mixed dementia (N = 1), at mild (N = 11) and moderate (N = 2) dementia stage. Participants were enrolled in an open-label trial of active music therapy group, set to take place once weekly for 60 minutes over a period of 12 weeks. Results: Participants experienced a slight improvement on cognition measured with Mini-Mental State Examination (p = 0.41), although without statistical significance and a statistically significant decrease in anxiety (p = 0.042) in post-intervention. There were no significant effects on quality of life and caregiver burden. Conclusions: Active music therapy is a promising intervention with good acceptance among participants. More studies with larger sample sizes are needed to confirm its effects and efficacy in cognitive and neuropsychiatric symptoms in dementia.